MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.49 8.76

Buy Sell

Overview

Share price change

24h

Current

Min

1.35

Max

1.49

Key metrics
By Trading Economics
Income	3.6M -34M
Sales	278K 1.9M
Profit margin	-1,786.576
Employees	181
EBITDA	979K -37M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+193.53% upside

Dividends
By Dow Jones
Next Earnings	10 lis 2025

Market Stats
By TradingEconomics
Market Cap	55M 163M
Previous open	-7.27
Previous close	1.49

News Sentiment

By Acuity

10%

90%

334 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 paź 2025, 20:45 UTC

Earnings

Costco Wholesale Sales Climb in September, Early October

8 paź 2025, 20:12 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 paź 2025, 16:39 UTC

Major Market Movers

Mining Shares Rise as Gold Prices Soar

8 paź 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 paź 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 paź 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Finance Acquisition Using Internal Funds

8 paź 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 paź 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 paź 2025, 21:54 UTC

Market Talk

Earnings

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 paź 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 paź 2025, 21:26 UTC

Market Talk

Earnings

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 paź 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 paź 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 paź 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs Will Remain a Publicly Traded Co >TASK

8 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 paź 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 paź 2025, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

8 paź 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 paź 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 paź 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 paź 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 paź 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 paź 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 paź 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 paź 2025, 15:43 UTC

Acquisitions, Mergers, Takeovers

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 paź 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

193.53% upside

12 Months Forecast

Average 4.08 USD 193.53%

High 7 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

334 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.